Credit Suisse Can Clearly See Why Johnson & Johnson Acquired Abbott's Optics Division


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


On September 16, Johnson & Johnson (NYSE: JNJ) announced plans to acquire Abbott Medical Optics for $4.325 billion in cash.

Credit Suisse’s Vamil Divan maintains a Neutral rating on Johnson & Johnson, with a price target of $123.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

The Deal

The deal is expected to close in Q1:17, and Divan expects the acquisition to be immediately accretive to Johnson & Johnson’s non-GAAP EPS.

“While not transformative by any means given JNJ’s overall size and scale, we believe this deal is a good strategic fit within JNJ’s existing vision care business,” the analyst mentioned.


FREE REPORT: How To Learn Options Trading Fast

In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, ​a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.


Given that the company has also undertaken deals in medical devices and consumer, Divan wondered whether management would now focus its attention of strengthening the pharmaceutical segment via business development.

Pricey Deal

While Abbott Medical Optics has three key business segments, including cataract surgery tools, refractive laser surgery tools and consumer eye health, Divan pointed out that Johnson & Johnson did not as yet have a presence in the vision surgical equipment field space, although the company did have expertise and scale in consumer vision brands and medical device manufacturing.

The analyst also noted that the price for the deal is higher than previous comparable deals by peers, while stating that the current deal could “create both revenue as well as COGS synergies through JNJ’s consumer brand equity, geographic footprint, as well as manufacturing scale.”

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: Analyst ColorNewsHealth CareReiterationM&AAnalyst RatingsGeneralAbbott Medical OpticsCredit SuisseVamil Divan